rectal cancer Clinical Trials and Research
Also known as: rectal adenocarcinoma, cancer of the rectum, rectum cancer, colorectal cancer, rectal tumor · ICD-10: C20
Rectal cancer is a type of cancer that begins in the rectum, the final section of the large intestine. Clinical trial research focuses on developing new treatments, improving existing therapies, and enhancing patient quality of life. Find a Trial helps patients search for active studies.
Common questions about rectal cancer clinical trials
What are the general eligibility requirements for rectal cancer clinical trials?
Eligibility criteria vary by study but often include age, cancer stage, overall health, and prior treatments. Patients must meet specific requirements to ensure safety and study relevance. This information is detailed on ClinicalTrials.gov.
What are the different phases of clinical trials for rectal cancer?
Clinical trials typically progress through phases 1, 2, and 3. Phase 1 assesses safety, phase 2 evaluates effectiveness, and phase 3 compares new treatments to standard care. Phase 4 studies post-market safety. Data is available on ClinicalTrials.gov.
Do clinical trials for rectal cancer cost money to participate in?
Generally, study-related medical costs, such as experimental treatments and tests, are covered by the trial sponsor. Routine care costs may be billed to insurance. Patients should always clarify financial responsibilities with the research team.
What new treatments are being investigated for rectal cancer?
Current research explores novel chemotherapy regimens, radiation techniques, targeted therapies, and immunotherapies. Studies also investigate organ preservation strategies and personalized treatment approaches. Information on these areas can be found on ClinicalTrials.gov and NIH RePORTER.
What types of interventions are commonly studied in rectal cancer clinical trials?
Common interventions include different surgical approaches, various forms of radiation therapy, and systemic treatments like chemotherapy, targeted drugs, and immunotherapy. Combinations of these therapies are also frequently investigated. Details are available on ClinicalTrials.gov.
Are there specific biomarkers relevant to rectal cancer clinical trials?
Yes, biomarkers like MSI status, RAS/BRAF mutations, and HER2 amplification are increasingly important for guiding treatment decisions and trial enrollment. Researchers are studying how these markers predict response to specific therapies. Data is often found on ClinicalTrials.gov and NIH RePORTER.
What are common reasons someone might be excluded from a rectal cancer clinical trial?
Common exclusion criteria can include certain pre-existing medical conditions, uncontrolled infections, specific prior treatments, or other cancers. These criteria help ensure patient safety and the integrity of study results. Details are listed on ClinicalTrials.gov.
Are there clinical trials for rectal cancer focusing on quality of life?
Yes, many trials incorporate quality of life assessments to understand the impact of treatments on daily living. Some studies specifically focus on supportive care, symptom management, and long-term survivorship issues for rectal cancer patients. Information is on ClinicalTrials.gov.
How to find a rectal cancer trial that fits you
- Describe your rectal cancer situation in detail — stage if applicable, prior treatments, age, and other relevant conditions.
- Use the location filter (worldwide, US, US & Canada, Europe) to narrow to trials near you.
- Review each trial's eligibility criteria carefully. Save 2–5 candidates with their NCT numbers.
- Discuss with your treating clinician before contacting the research site.
Browse all rectal cancer trials →